Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287
A phase 3 trial of Pembrolizumab, Sacituzumab tirumotecan, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] is a phase 3 interventional study registered as NCT06422143 by Merck Sharp & Dohme LLC, with 851 participants planned, started 2024-06-10 and due to reach its primary completion in 2029-01-12. Interventions recorded: Pembrolizumab, sac-TMT, Carboplatin, Paclitaxel, Nab-paclitaxel. Conditions listed: Non-small Cell Lung Cancer, NSCLC. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With P
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Pembrolizumab, Small-cell lung cancer.
- TrialA Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Shares Paclitaxel / nab-paclitaxel, Merck & Co. (MSD), Carboplatin, Pembrolizumab.
- TrialStudy of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan
Shares Paclitaxel / nab-paclitaxel, Merck & Co. (MSD), Carboplatin, Pembrolizumab.
- TrialA Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-34
Shares Paclitaxel / nab-paclitaxel, Merck & Co. (MSD), Carboplatin, Pembrolizumab.
- TrialA Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Carboplatin, Pembrolizumab.
- TrialSacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, A
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Carboplatin, Small-cell lung cancer.
- TrialA Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc
Shares Sacituzumab tirumotecan, Paclitaxel / nab-paclitaxel, Merck & Co. (MSD), Carboplatin.
- TrialA Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan
Shares Sacituzumab tirumotecan, Paclitaxel / nab-paclitaxel, Merck & Co. (MSD), Carboplatin.